171 related articles for article (PubMed ID: 36047474)
1. An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
Valenzuela B; Olsson Gisleskog P; Poggesi I; Sidorenko T; Burcklen M; Kracker H; Pérez-Ruixo JJ
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1294-1304. PubMed ID: 36047474
[TBL] [Abstract][Full Text] [Related]
2. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
[No Abstract] [Full Text] [Related]
4. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
5. An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Gisleskog PO; Valenzuela B; Scherz T; Burcklen M; Pérez-Ruixo JJ; Poggesi I
Clin Pharmacokinet; 2021 Sep; 60(9):1227-1237. PubMed ID: 33914286
[TBL] [Abstract][Full Text] [Related]
6. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS; Pozzilli C; Havrdova EK; Lemle A; Burcklen M; Larbalestier A; Hennessy B; Sidorenko T; Vaclavkova A; Olsson T;
Neurology; 2022 Aug; 99(8):e762-e774. PubMed ID: 35667837
[TBL] [Abstract][Full Text] [Related]
7. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
9. Ponesimod (Ponvory) for multiple sclerosis.
Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
[No Abstract] [Full Text] [Related]
10. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
Tan H; Li X; Li Y; He F; ZhangBao J; Zhou L; Yang L; Zhao C; Lu C; Dong Q; Li H; Quan C
Front Immunol; 2024; 15():1343531. PubMed ID: 38558796
[TBL] [Abstract][Full Text] [Related]
11. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
Jiang T; Ziemssen T; Wray S; Shen C; Söderbärg K; Lewin JB; Božin I; Freedman MS
CNS Drugs; 2023 May; 37(5):441-452. PubMed ID: 37155132
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
[TBL] [Abstract][Full Text] [Related]
13. It is time to rethink clinical trials on Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Barboza A
Mult Scler Relat Disord; 2024 Feb; 82():105395. PubMed ID: 38184909
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
Swallow E; Pham T; Patterson-Lomba O; Yin L; Gomez-Lievano A; Liu J; Tencer T; Gupte-Singh K
Mult Scler Relat Disord; 2023 Mar; 71():104551. PubMed ID: 36791623
[TBL] [Abstract][Full Text] [Related]
15. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
Mukhtar H; Yasmeen U; Siddiqa S; Sarfraz Z; Sarfraz A
Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
[TBL] [Abstract][Full Text] [Related]
19. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Olsson T; Boster A; Fernández Ó; Freedman MS; Pozzilli C; Bach D; Berkani O; Mueller MS; Sidorenko T; Radue EW; Melanson M
J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1198-208. PubMed ID: 24659797
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
